New drug duo aims to starve tough pancreatic tumors
NCT ID NCT05034627
Summary
This early-stage study is testing a new combination of two drugs, calaspargase pegol and cobimetinib, for people with advanced pancreatic cancer that has spread. The main goal is to find the safest and most effective dose. Researchers hope the two drugs will work together to cut off a key nutrient for cancer cells, potentially helping to control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.